First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-Jul-2025 22:10 ET (6-Jul-2025 02:10 GMT/UTC)
Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy. This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD positive but BRCA wild-type, a demographic less extensively explored in previous research. The primary goal was to assess the 1-year progression-free survival (PFS) rate of olaparib maintenance therapy in this specific patient group, offering insights into its potential as a therapeutic option.
Jilin University-A new study published in the Journal of Science Bulletin proposed an innovative conceptual mechanism known as the “orbital stabilisation effect” for the precise design of novel Sb-based single-atom catalysts (SACs) to achieve high activity and ultra-long durability in the oxygen reduction reaction (ORR).
In a paper published in National Science Review, a bottom-up isoprene emission inventory, including both biogenic and combustion sources, was developed and used to model the contributions of isoprene to secondary organic aerosol formation in China. The results show that emissions of isoprene from combustion sources contributed substantially to ambient secondary organic aerosol, particularly during winter.